dr. perez-soler on impact of osimertinib on field of nsclc
Published 7 years ago • 150 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
1:54
dr. perez-soler on the future of lung cancer therapies
-
1:58
dr. perez-soler on efficiency of ngs in lung cancer
-
1:13
dr. perez-soler on improved outlook for patients with lung cancer
-
1:17
dr. perez-soler discusses treatment options for nsclc
-
2:09
dr. perez-soler on immunotherapy advances in sclc
-
1:29
dr. roman perez-soler on the correlation between erlotinib-induced skin rash and overall survival
-
1:06
dr. shum on patient consultation of osimertinib in nsclc
-
42:50
dr giselle sholler dfmo, when & how it is used
-
0:36
dr. camidge on the fda approval of pembrolizumab for squamous nsclc
-
1:03
sangeetha palakurthi on fda approval of atezolizumab in nsclc
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:13
dr. roman perez-soler on treating nsclc after first-line treatments
-
0:54
dr. morgensztern on impact of immunotherapy on nsclc field
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
0:59
dr. west on emerging changes in the field of egfr-mutant nsclc
-
2:34
dr. perez-soler on the challenges oncologists face in lung cancer
-
2:56
dr. román pérez-soler discusses the use of targeted therapies in lung cancer
-
6:06
osimertinib, the standard for egfr nsclc
-
1:16
dr. goldberg on options after developing resistance to osimertinib for nsclc